CREST Syndrome: Clinical Features
CREST syndrome is a limited cutaneous variant of systemic sclerosis characterized by five specific clinical features: Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasias 1.
Core Clinical Features
The acronym CREST defines the five cardinal manifestations:
C - Calcinosis
- Dystrophic calcium deposits in subcutaneous tissues
- Most commonly affects fingers, hands, and pressure points
- Can be painful and may ulcerate through the skin
- Appears as firm, white nodular lesions
- Represents a key distinguishing element that differentiates CREST from other systemic sclerosis subsets 2
R - Raynaud Phenomenon
- Present in nearly all patients with systemic sclerosis (>95%) 1
- Episodic vasospasm triggered by cold or stress
- Classic triphasic color changes: white (ischemia) → blue (cyanosis) → red (reperfusion)
- Often precedes other manifestations by years
- Associated with cold sensitivity and finger pain 3
- Can lead to digital ulcers in approximately 50% of patients 1
E - Esophageal Dysmotility
- Gastrointestinal involvement affects nearly 90% of systemic sclerosis patients 1
- Esophagus is the most commonly affected GI organ
- Manifests as dysphagia, reflux, and heartburn
- Results from smooth muscle atrophy and fibrosis
- Can lead to severe GERD complications if untreated
S - Sclerodactyly
- Skin thickening and tightening of the fingers and hands
- Creates a "claw-like" appearance with limited finger mobility
- Skin becomes shiny, tight, and bound down to underlying structures
- Restricted to areas distal to elbows/knees in limited cutaneous disease 1
T - Telangiectasias
- Dilated superficial blood vessels appearing as small red spots
- Commonly on face, hands, lips, and oral mucosa
- Mat-like or punctate appearance
- Blanch with pressure
Diagnostic Considerations
Diagnosis requires at least three of the five CREST features to be present 4, 5, 2. However, the full pentad is uncommon and typically develops gradually over many years 4.
Laboratory Findings
- Anticentromere antibodies are highly characteristic and specific for limited cutaneous systemic sclerosis/CREST 4, 5
- Positive antinuclear antibodies (ANA) 4, 6
- These autoantibodies are crucial for diagnosis alongside clinical features 5
Important Clinical Nuances
Three features (Raynaud phenomenon, sclerodactyly, and esophageal dysmotility) commonly occur in both limited and diffuse systemic sclerosis subsets 2. Their presence alone does not define CREST syndrome. Calcinosis appears to be the key distinguishing element that characterizes CREST syndrome specifically 2.
Disease Pattern and Prognosis
- CREST represents the limited cutaneous subset of systemic sclerosis 1
- Skin involvement restricted to hands, face, and distal extremities (below elbows/knees)
- Generally has a more favorable prognosis than diffuse cutaneous systemic sclerosis
- However, patients remain at risk for serious complications including:
Common Pitfalls
- Do not dismiss early Raynaud phenomenon - it may precede full CREST manifestation by several years 1
- Screen for pulmonary complications even in limited disease, as both PAH and ILD can occur 1
- Monitor blood pressure in early disease to detect scleroderma renal crisis, particularly with anti-RNA polymerase III antibodies 1
- Recognize oral manifestations including xerostomia and increased susceptibility to candidiasis 6
- Consider autoimmune hypothyroidism as a potential associated condition requiring monitoring 3